KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Receivables (2017 - 2025)

Alnylam Pharmaceuticals' Change in Receivables history spans 17 years, with the latest figure at -$184.2 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 409.62% year-over-year to -$184.2 million; the TTM value through Dec 2025 reached $360.0 million, up 315.9%, while the annual FY2025 figure was $360.0 million, 315.9% up from the prior year.
  • Change in Receivables reached -$184.2 million in Q4 2025 per ALNY's latest filing, down from $399.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $399.9 million in Q3 2025 to a low of -$184.2 million in Q4 2025.
  • Average Change in Receivables over 5 years is $34.1 million, with a median of $9.1 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: tumbled 470.68% in 2022, then surged 1913.17% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $59.4 million in 2021, then fell by 10.4% to $53.3 million in 2022, then crashed by 107.26% to -$3.9 million in 2023, then soared by 1638.07% to $59.5 million in 2024, then plummeted by 409.62% to -$184.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Change in Receivables are -$184.2 million (Q4 2025), $399.9 million (Q3 2025), and $136.9 million (Q2 2025).